Protocol Design and Performance Benchmarks by Phase and by Oncology and Rare Disease Subgroups-Reference-Cited by-同舟云学术

Protocol Design and Performance Benchmarks by Phase and by Oncology and Rare Disease Subgroups

Published:2022-08-12 Issue:1 Volume:57 Page:49-56
ISSN:2168-4790
Container-title:Therapeutic Innovation & Regulatory Science
language:en
Short-container-title:Ther Innov Regul Sci

Author:

Getz Kenneth^ORCID,Smith Zachary,Kravet Marcy

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Link

https://link.springer.com/content/pdf/10.1007/s43441-022-00438-5.pdf

Reference19 articles.

1. Sampler S. Tracking protocol complexity. GCPJ. 2000;7(2):6–8.

2. Vogel J, Getz K. Factors driving the increases use of contractors in drug development. Clin Res Reg Affairs. 1997;14(4):177–90.

3. Maloy J, Getz K, Hovde M. Clinical research in transition. Monitor. 2001;15:31–6.

4. Kahn M, Broverman C, Wu N, Farnsworth W, Manlapaz-Espiritu L. Improving protocol quality. Appl Clin Trials. 2002;11:40–50.

5. Rai S. Drug companies cut costs with foreign clinical trials. The New York Times. 2005. http://www.nytimes.com/2005/02/24/business/24clinic.html?8bl.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the Value of Integrated Evidence Approaches in Drug Development;2024-04-29

2. Benchmarking Site Activation and Patient Enrollment;Therapeutic Innovation & Regulatory Science;2024-04-03

3. New Benchmarks on Protocol Amendment Experience in Oncology Clinical Trials;Therapeutic Innovation & Regulatory Science;2024-03-26

4. New Benchmarks on Protocol Amendment Practices, Trends and their Impact on Clinical Trial Performance;Therapeutic Innovation & Regulatory Science;2024-03-04

5. New Benchmarks on Protocol Amendment Experience in Oncology Clinical Trials;2023-12-07